StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report published on Friday. The brokerage issued a hold rating on the stock.

Tonix Pharmaceuticals Price Performance

TNXP opened at $0.24 on Friday. The company has a fifty day moving average price of $0.26 and a two-hundred day moving average price of $0.30. The firm has a market capitalization of $44.01 million, a PE ratio of 0.00 and a beta of 2.02. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $12.48. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. As a group, analysts anticipate that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.